Chris A. Mason

London, ENG WC1E6BT, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications

Engineering an Autonucleolytic Mammalian Suspension Host Cell Line to Reduce DNA Impurity Levels in Serum-Free Lentiviral Process Streams.

Engineering an Autonucleolytic Mammalian Suspension Host Cell Line to Reduce DNA Impurity Levels in Serum-Free Lentiviral Process Streams.

Journal: ACS synthetic biology
Published: January 24, 2024

An autonucleolytic suspension HEK293F host cell line for high-titer serum-free AAV5 and AAV9 production with reduced levels of DNA impurity.

An autonucleolytic suspension HEK293F host cell line for high-titer serum-free AAV5 and AAV9 production with reduced levels of DNA impurity.

Journal: Molecular therapy. Methods & clinical development
Published: November 20, 2023

Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations.

Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 09, 2023

Serum-free lentiviral vector production is compatible with medium-resident nuclease activity arising from adherent HEK293T host cells engineered with a nuclease-encoding transgene.

Serum-free lentiviral vector production is compatible with medium-resident nuclease activity arising from adherent HEK293T host cells engineered with a nuclease-encoding transgene.

Journal: Heliyon
Published: February 13, 2023

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.

Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.

Journal: Clinical and experimental immunology
Published: September 27, 2022

Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease.

Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease.

Journal: Molecular therapy. Methods & clinical development
Published: February 22, 2022

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Journal: bioRxiv : the preprint server for biology
Published: January 04, 2022

Gene Therapy Developments for Pompe Disease.

Gene Therapy Developments for Pompe Disease.

Journal: Biomedicines
Published: January 02, 2022

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Journal: Cell
Published: December 01, 2021

High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing.

High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 12, 2021

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.

The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants.

Journal: Cell host & microbe
Published: August 19, 2021

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

Journal: Cell
Published: May 25, 2021
Showing 1-12 of 80

Last Updated: 09/26/2026